Title: Three musketeers making smart drugs

Publication: Bio & U health / Joon Ki Lee

Date: 11 March 2008

Summary 

• Focusing on developing Antibiotics, Anticoagulants, Anticancer and ADC technology, LegoChem, a KOSDAQ enlisted company, is now showing off its technological advancement by licensing-out its technologies to or collaborating with global and national pharmaceutical companies. 

• Dr. Yong-Zu Kim, CEO of LegoChem, is one of few nationwide experts in drug development, who played a leading role in the development of FACTIVE, the first drug in Korea approved by the US FDA.  

• LegoChem is a research-oriented company committed to ethical and transparent management.  

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).